Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: a historical perspective.
This tribute to Bruce Merrifield traces the author's fortuitous path in 1964 from Vincent du Vigneaud's laboratory to the laboratory of D. W. Woolley to learn the solid phase method and then to his first faculty position in the Department of Biochemistry, McGill University, Montreal in 1965. It recalls the key roles played from early 1966 to July 1967 by Bruce Merrifield, John Stewart, Arnold Marglin, Herb Takashima, and Vincent du Vigneaud in providing key advice to the author's efforts to use the solid phase method to synthesize oxytocin; while simultaneously the du Vigneaud and Merrifield laboratories were collaborating on the solid phase synthesis of deamino-oxytocin. Both syntheses were published in the same issue of the Journal of American Chemical Society in 1968. Also described is how this breakthrough impacted the author's scientific career: by leading to highly productive collaborative studies, initially with Wilbur H. Sawyer and subsequently with others, on the design and synthesis of selective agonists, antagonists, and radioiodinated ligands for oxytocin and vasopressin receptors. These syntheses were greatly facilitated by the contributions of highly talented graduate students, research technicians, and visiting peptide chemists from Hungary, England, Poland, Bulgaria, and China. Many of these peptides have become very valuable pharmacological tools in studies on the peripheral and central effects of oxytocin and vasopressin: further attesting to the profound impact of the solid phase method as the cornerstone for all the discoveries, which he and his collaborators and coworkers have made over the past 40 years.
Manning
Maurice
M
Department of Biochemistry and Cancer Biology, University of Toledo College of Medicine, Toledo, OH 43614-2598, USA. maurice.manning@utoledo.edu
D000595:Amino Acid Sequence; D000959:Antihypertensive Agents / Q000494:pharmacology; D015195:Drug Design; D049673:History, 20th Century; D010121:Oxytocin / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000266:history; D014481:United States; D014667:Vasopressins / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000266:history
D000959:Antihypertensive Agents; D014667:Vasopressins; D010121:Oxytocin